Iterum Therapeutics Q4 Adj EPS $(0.81) Beats $(0.93) Estimate
Portfolio Pulse from Benzinga Newsdesk
Iterum Therapeutics (NASDAQ:ITRM) reported Q4 adjusted EPS losses of $(0.81), surpassing the analyst consensus estimate of $(0.93) by 12.9%. However, this represents a 55.77% increase in losses compared to $(0.52) per share from the same period last year.
March 28, 2024 | 12:50 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Iterum Therapeutics reported a smaller-than-expected Q4 loss per share, but the loss widened significantly from the previous year.
While beating EPS estimates typically has a positive impact on stock prices, the significant year-over-year increase in losses could temper investor enthusiasm. The mixed nature of the report suggests a neutral short-term impact on ITRM's stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100